Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Apr 15, 2021- IDE397 demonstrates significant single-agent anti-tumor activity in a 40-plus MTAP-deletion PDX study, including tumor regressions, across major solid tumor types, such as NSCLC, gastric, esophageal, and bladder cancers (AACR 2021)
-
Mar 23, 2021- Initiated Phase 1 clinical trial for IDE397, a potential best-in-class MAT2A inhibitor for patients having tumors with MTAP-deletion
-
Mar 23, 2021- Targeting enrollment of approximately 40 patients in the IDE196 and binimetinib clinical combination Phase 1/2 study in MUM
